Health
Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada
TORONTO, December 09, 2025--Biogen Canada Inc. today announced that Health Canada has issued a Notice of Compliance (NOC) for ZURZUVAE™ (zuranolone) for the treatment of moderate or severe postpartum depression (PPD) in adults following childbirth. ZURZUVAE is a once-daily, 14-day oral single course treatment for women with PPD. This first-of-its-kind treatment offers relief from depressive symptoms, with benefits seen in clinical studies as early as day 3, significant reduction of symptoms by t
About this update from Biogen Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/5358514a2900ea4ccdc57d9213b49faa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QT6Wk6V2h9oEr_YNf8cV7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5358514a2900ea4ccdc57d9213b49faa","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/lWFkqgVnoZ0zZGG42eUsLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/5358514a2900ea4ccdc57d9213b49faa","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Postpartum depression (PPD) affects up to one in five Canadian women1; it is the most common complication2 related to childbearing and a leading cause of maternal death in Canada3","length":179,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Left untreated, PPD can have short- and long-term consequences on maternal health, child development and family well-being4,5,6","length":127,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"ZURZUVAE is a 14-day, oral single course of treatment that offers relief from depressive symptoms as early as Day 3, a significant step forward from the current standards of PPD care","length":182,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":488,"olType":false},{"type":"text","content":"TORONTO, December 09, 2025--(BUSINESS WIRE)--Biogen Canada Inc. today announced that Health Canada has issued a Notice of Compliance (NOC) for ZURZUVAE™ (zuranolone) for the treatment of moderate or severe postpartum depression (PPD) in adults following childbirth. ZURZUVAE is a once-daily, 14-day oral single course treatment for women with PPD. This first-of-its-kind treatment offers relief from depressive symptoms, with benefits seen in clinical studies as early as day 3, significant reduction of symptoms by the end of treatment at Day 15, and sustained effect through day 45 compared to placebo.","length":604,"tagName":"p"},{"type":"text","content":"ZURZUVAE offers a novel therapeutic approach due to its onset as early as Day 3 and a targeted mode of action that addresses mood dysregulation thought ...